Body kills 'spontaneous' blood cancers on a daily basis, research finds

February 2, 2014, Walter and Eliza Hall Institute
Associate Professor David Tarlinton, Dr. Stephen Nutt and Dr. Axel Kallies from the Walter and Eliza Hall Institute have found that the immune system removes errant B cells before they become cancerous. Credit: Walter and Eliza Hall Institute

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found.

The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as non-Hodgkin's lymphomas). The results of the study were published today in the journal Nature Medicine.

This immune surveillance accounts for what researchers at the institute call the 'surprising rarity' of B-cell lymphomas in the population, given how often these spontaneous changes occur. The discovery could lead to the development of an early-warning test that identifies patients at high risk of developing B-cell lymphomas, enabling proactive treatment to prevent tumours from growing.

Dr Axel Kallies, Associate Professor David Tarlinton, Dr Stephen Nutt and colleagues made the discovery while investigating the development of B-cell lymphomas.

Dr Kallies said the discovery provided an answer to why B-cell lymphomas occur in the population less frequently than expected. "Each and every one of us has spontaneous mutations in our immune B cells that occur as a result of their normal function," Dr Kallies said. "It is then somewhat of a paradox that B cell lymphoma is not more common in the population.

"Our finding that immune surveillance by T cells enables early detection and elimination of these cancerous and pre-cancerous cells provides an answer to this puzzle, and proves that is essential to preventing the development of this blood cancer."

B-cell lymphoma is the most common blood cancer in Australia, with approximately 2800 people diagnosed each year and patients with a weakened immune system are at a higher risk of developing the disease.

The research team made the discovery while investigating how B cells change when lymphoma develops. "As part of the research, we 'disabled' the T cells to suppress the immune system and, to our surprise, found that lymphoma developed in a matter of weeks, where it would normally take years," Dr Kallies said. "It seems that our immune system is better equipped than we imagined to identify and eliminate cancerous B cells, a process that is driven by the immune T cells in our body."

Associate Professor Tarlinton said the research would enable scientists to identify pre-cancerous cells in the initial stages of their development, enabling early intervention for patients at risk of developing B-cell lymphoma.

"In the majority of patients, the first sign that something is wrong is finding an established tumour, which in many cases is difficult to treat" Associate Professor Tarlinton said. "Now that we know B-cell lymphoma is suppressed by the , we could use this information to develop a diagnostic test that identifies people in early stages of this disease, before tumours develop and they progress to cancer. There are already therapies that could remove these 'aberrant' B in at-risk patients, so once a test is developed it can be rapidly moved towards clinical use."

Explore further: Cancer Research UK launches trial of new lymphoma treatment

More information: Fas ligand–mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas, DOI: 10.1038/nm.3442

Related Stories

Cancer Research UK launches trial of new lymphoma treatment

January 29, 2014
Cancer Research UK's Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body's own immune system to attack cancerous B-cells growing out of control.

Survival protein a potential new target for many cancers

January 7, 2014
Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.

'Performance-enhancing' boost helps to fight infection

September 23, 2013
(Medical Xpress)—Melbourne researchers have found that even our immune system is subject to performance enhancement, giving immune cells the boost they need to ensure the best team is selected to fight infections.

Missing immune response may prove a vital link for new leukaemia treatments

September 20, 2013
(Medical Xpress)—Patients suffering from leukaemia could have their immune system engineered to fight the disease, after scientists at the University of Birmingham discovered that they lacked an immune response to a certain ...

New weapon fights drug-resistant tumors

January 30, 2014
Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

210
4.5 / 5 (2) Feb 02, 2014
This is tremendous! This is a story that puts one to mind of other amazing discoveries occurring with greater and greater frequency in the last ten years. Taken as a whole, it really does open a much broader range of hope for the curing and prevention of so many diseases. If we can just keep this kind of work funded, and avoid a conflict that leads to global catastrophe, we have a chance! I can see it!

word-to-ya-muthas

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.